Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TA-7284 in Type 2 Diabetes Mellitus
NCT00707954Phase 2Completed
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Jun 2008
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing TA-7284 with Placebo (2 arms). Primary endpoints: Adverse Events at 19 days and Adverse Drug Reactions at 19 days. Started Jun 2008; status: completed.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00707954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00707954.